Infinity Pharmaceuticals | INFI - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 538M 2026-03
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Cipla INR 60.98B 1.06B 2025-12
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 11.29M 1.51M 2025-12
CSL USD 5.7B 2.82B 2025-12
Eisai JPY 199.9B 16.22B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Grifols EUR 1.99B 217.4M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Infinity Pharmaceuticals USD 10.7M 1.54M 2023-06
Ionis Pharmaceuticals USD 364M 54M 2026-03
J&J USD 17.44B 1.53B 2026-03
Novartis USD 9.29B 507M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Plus Therapeutics USD 7.11M 1.23M 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
TG Therapeutics USD 170.12M 28.04M 2026-03